RNXT (RenovoRx) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


RNXT RenovoRx Inc RNXT
31 GF Score
Price $0.93
! 2 Warning Signs
View Full Analysis

What is RenovoRx Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

RenovoRx's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

RNXT vs NNVC, KALA, PSTV: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, RenovoRx's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RenovoRx Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where RenovoRx's Margin of Safety % (DCF FCF Based) falls into.


RNXT
31GF Score
RenovoRx Inc RNXT
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RenovoRx Business Description

Address 2570 West El Camino Real, Suite 320, Mountain View, CA, USA, 94040
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
31GF Score

Get the complete analysis for RNXT

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price